PBAC to consider 'significant changes' for hepatitis C (HCV)

PBAC to consider 'significant changes' for hepatitis C (HCV)

The PBAC has recommended a number of revisions to the PBS listing of the direct-acting antivirals for hepatitis C with more "significant changes" on the horizon. This follows "issues raised" at the Hepatitis C stakeholder meeting held in late 2018, which included researchers, clinician and patient groups, were required to sign a confidentiality agreement. Companies with PBS-listed direct-acting antivirals were not invited to the meeting.

Read More